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Overexpression of the transmembrane tyrosine phosphatase
LAR activates the caspase pathway and induces apoptosis
Liang-Ping Weng, Junying Yuan* and Qiang Yu
Background: The protein tyrosine phosphatase family comprises transmembrane
receptor-like and cytosolic forms. Although the exact biological functions of these
enzymes are largely unknown, they are believed to counter-balance the effects of
protein tyrosine kinases. We have previously identified and characterized a
mammalian transmembrane protein tyrosine phosphatase, called LAR (leukocyte
common antigen related gene), whose expression is often associated with
proliferating epithelial cells or epithelial progenitor cells. This study investigates
the potential role of LAR in the regulation of cell growth and death in mammals.
Results: We overexpressed in mammalian cells in culture either the full-length
wild-type LAR or a truncation mutant containing only the extracellular domain of
the molecule, and found that whereas the truncated LAR could be readily
overexpressed in various cell lines, cells overexpressing the wild-type LAR were
negatively selected. Using an inducible expression system, we demonstrated
that overexpression of the wild-type LAR, but not the truncated LAR, activated
the caspase pathway directly and induced p53-independent apoptosis.
Conclusion: Our data suggest that LAR might regulate cellular signals essential
for cell survival. Overproduction of LAR may tilt the balance between the
tyrosine phosphorylation and dephosphorylation of proteins whose activities are
critical for cell survival, and therefore lead to cell death. In addition, our
observations that overexpression of LAR induces cell death without affecting
cell adhesion suggest that LAR may activate the caspase pathway and induce
cell death directly. This work is the first example of the involvement of a
receptor-like protein tyrosine phosphatase in cell-death control and provides the
basis for searching for molecules and mechanisms linking signal transduction by
protein tyrosine phosphorylation to the caspase-mediated cell-death pathway. 
Background
Signal transduction involving protein tyrosine phospho-
rylation cascades is a fundamental cellular mechanism
regulating cell survival, growth, differentiation and
migration. The tyrosine phosphorylation status of a
protein is controlled by two antagonistic families of
enzymes, protein tyrosine kinases, which add phos-
phate, and protein tyrosine phosphatases, which remove
phosphate. The protein tyrosine kinases, which were
originally discovered as biologically important molecules
such as retroviral oncoproteins and growth factor
receptors, have been studied extensively during the past
two decades and their significance in cellular physiology
is widely appreciated. The protein tyrosine phos-
phatases, on the other hand, were mostly identified
based on their sequence homology to pre-existing
tyrosine phosphatases that were defined by their enzy-
matic activities in vitro. In comparison with the tyrosine
kinases therefore, the tyrosine phosphatases are much
less well studied and their biological functions are
poorly understood.
LAR is a member of a family of transmembrane, receptor-
like protein tyrosine phosphatases or PTPs [1–4], origi-
nally identified by sequence homology to the leukocyte
common antigen CD45 [1]. LAR expression is detected in
a wide variety of tissues and is regulated during develop-
ment [5]. In cultured cells, the levels of LAR mRNA and
protein are influenced by growth factors and cell density
[6,7]. Structural and biochemical characterization of LAR
suggest that it might participate in transmembrane signal-
ing involving protein tyrosine phosphorylation by counter-
balancing the activity of the protein tyrosine kinases [1,2].
Functional studies of LAR in cultured cells suggest that it
might have a role in regulating signal transduction medi-
ated by receptor tyrosine kinases [8–12]. Attempts to find
physiological substrates of LAR using interaction-trap
strategies identified two proteins that physically interact
with LAR: one colocalized with LAR at focal adhesions of
human breast adenocarcinoma cells [13] and the other
contained guanine nucleotide exchange factor domains of
the Rac/Rho family of GTPases [14], suggesting that LAR
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may also function in regulating cell adhesion, migration
and/or signaling mediated by the focal adhesion complex.
There is also evidence that the Drosophila homolog of
LAR, DLAR, is selectively expressed in central nervous
system and is required for motor axon guidance during
embryonic development, presumably by regulating cell
adhesion [15,16]. Taken together, these observations
suggest that LAR might be a multifunctional protein and
have roles in diverse aspects of cell physiology involving
regulation of protein tyrosine phosphorylation.
Programed cell death or apoptosis is a fundamental part of
tissue homeostasis during normal development and in
pathological conditions [17]. The cell death machinery is
regulated by both internal genetic programs and external
physiological stimuli. Studies of the molecular pathways,
mechanisms and regulation of the cell death process have
revealed three gene families that are the central compo-
nents of apoptotic pathways: the tumor necrosis factor
(TNF) family and their receptors [18], the interleukin-1 β-
converting enzyme (ICE) or caspase family of cysteine
proteases [19] and the proto-oncogenes of the bcl-2 gene
family [20]. At the same time, a large number of mole-
cules, which normally function in directing cell prolifera-
tion and differentiation, have been found to be involved
in regulating apoptotic pathways [21].
Protein tyrosine phosphorylation and tyrosine kinases
have been implicated as playing critical roles in regulating
cell survival. For example, in addition to its ability to
promote cell proliferation and differentiation, the basic
fibroblast growth factor (bFGF), by activating tyrosine
kinase activity of its receptor, is a potent suppressor of
programed cell death during development of the limb bud
[22], lens fibre cells in the mouse [23], and during TNFα-
induced apoptosis [24]. Insulin and insulin-like growth
factor (IGF) are effective inhibitors of apoptosis induced
by trophic factor removal [25] and overexpression of 
c-Myc [26] or ICE [27]. Activation of survival pathways
that involve insulin and IGF has been hypothesized to be
mediated by tyrosine phosphorylation activity of the
insulin and IGF receptors and by phosphatidylinositol 3-
kinase [28,29]. These results suggest that tyrosine
phosphorylation of certain proteins is critical for cell sur-
vival. The involvement of PTPs in cell-death control has
been suggested by a number of experiments using tyro-
sine phosphatase inhibitors [30,31], in which apoptosis
was found to be inhibited following inactivation of tyro-
sine phosphatases. The exact roles of tyrosine phos-
phatases in these experiments and in cell-death control in
general, are however not clear.
To define the biological functions of LAR and to investi-
gate the potential role of PTPs in regulating cell growth,
death and differentiation, we overexpressed LAR in
various mammalian cell lines. We found that overexpres-
sion of LAR in many types of cells, especially nontrans-
formed cells, was cytotoxic. Using an inducible expression
system, we demonstrated that overexpression of LAR acti-
vated the caspase pathway and induced apoptosis. Our
results suggest that, in mammalian cells, LAR and LAR-
like PTPs might play a role in regulating tyrosine phos-
phorylation of a set of proteins which are critical for cell
growth and survival. These proteins are important because
they might function to link signal transduction pathways
involving protein phosphorylation cascades with the
caspase-mediated cell-death pathway. Our study provides
an assay system to search for these proteins. This is the
first demonstration of the involvement of a receptor-like
PTPs in the regulaton of cell death.
Results
Cells overexpressing wild-type LAR are negatively selected
To investigate possible roles of LAR in signal transduc-
tion and regulation of cell growth, we attempted to alter
LAR activity by overexpressing wild-type and mutant
LAR in cultured cells. Two expression constructs were
generated, one encoding the full-length wild-type LAR,
and the other encoding only the extracellular domain of
LAR (Figure 1). The two constructs were tested in COS-7
cells by transient transfection followed by immunoprecipi-
tation assays. Both proteins were expressed at comparable
levels in COS-7 cells (Figure 2). Cells transfected with the
wild-type LAR cDNA expressed three protein species, a
190 kDa precursor, a 145 kDa proteolytically cleaved
extracellular domain subunit and a 85 kDa intracellular
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Figure 1
The full-length wild-type LAR and the
truncated LAR mutant, LAR-∆TP, which
contains only the extracellular domain of LAR.
The full-length LAR has an extracellular
portion composed of immunoglobulin-like
domains and fibronectin type III repeats and
an intracellular portion containing two
tandemly repeated phosphatase domains.
Notice that the LAR protein is cleaved into
two subunits which remain associated by a
non-covalent linkage [2].
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phosphatase-domain-containing subunit [2]. Cells trans-
fected with the truncated LAR cDNA, on the other hand,
expressed only the 145 kDa subunit (Figure 2). 
We next tried to establish stable cell clones that overpro-
duce LAR. We introduced the two cDNA expression con-
structs by transfection into a rat embryonic fibroblast cell
line 208F, from which the rat LAR cDNA was previously
isolated and in which the LAR protein was characterized
[2]. Although we could obtain drug-resistant colonies from
both transfections, the number of  colonies obtained from
the cells transfected with wild-type LAR was consistently
less than the number obtained with the truncated LAR
(data not shown). Furthermore, most of the clones that
were transfected with wild-type LAR showed either no
increase or less than onefold increase in LAR protein level
when analyzed by western blotting or by immunoprecipita-
tion (Figure 3 and data not shown). The few LAR-express-
ing clones, obtained from transfections with the wild-type
LAR, expressed aberrant forms of the protein (Figure 3 and
data not shown). In contrast, more than 50% of the clones
transfected with the truncated LAR cDNA expressed
5–10-fold higher levels of the mutant LAR protein over
those of the endogenous LAR protein (Figure 3 and data
not shown). It appeared that overexpression of wild-type
LAR in rat fibroblasts had negative effects on cell growth,
resulting in negative selection against cells overexpressing
the LAR protein. The only cells which could grow after
transfection were the cells which had no increase or very
small increases in LAR expression or expressed aberrant
forms of the LAR protein. Overexpression of truncated
LAR did not affect cell morphology, growth or protein
tyrosine phosphorylation (data not shown). 
Overexpression of LAR induces cell death
To understand the reason for the failure to obtain stable
transfectants that overproduce wild-type LAR, we tran-
siently co-transfected the 208F cells with an indicator
plasmid encoding the Escherichia coli β-galactosidase
protein, together with either of the two LAR expression
plasmids. As controls, we co-transfected the cells with the
vector plasmid or with a plasmid expressing ICE, which is
known to induce apoptosis when overexpressed in rat
fibroblast cells [32].
The number and the morphology of the transfected cells
were analyzed 24 hours after transfection. As shown in
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Figure 2
Transient expression of LAR in COS-7 cells. COS-7 cells were
transiently transfected either with a construct that encodes the wild-type
LAR or one that encodes the truncated LAR-∆TP. Expression of LAR
protein was analyzed by immunoprecipitation of [35S]methionine-labeled
proteins from the transfected COS-7 cells using anti-LAR antiserum α-
294. The control is an immunoprecipitate from untransfected COS-7
cells. The 190 kDa precursor of LAR is indicated, as are the 145 kDa
extracellular and 85 kDa phosphatase-containing subunits, which
become dissociated under the denaturing conditions of SDS–PAGE.
The band below the 85 kDa subunit is a degradation product of LAR.
C
on
tr
ol
kDa
200–
190
145
185
68–
97–
LA
R
LA
R
-∆
TP
Current Biology
Figure 3
Western blot analysis of LAR expression in stable transfectants. Rat
fibroblast 208F cells were transfected with the wild-type LAR or the
truncated LAR-∆TP. After selection, stably transfected clones were
isolated. Equal amounts of total protein from the isolated clones were
analyzed by western blotting using anti-LAR antiserum αN-131, which
recognizes only the 145 kDa extracellular subunit of LAR (arrowheads).
Protein samples are numbered according to the isolated clones.
Notice that, in lanes 10 and 11 for the wild-type LAR transfection, two
aberrant LAR proteins were expressed.
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Figure 4, about 30% of the β-galactosidase-positive cells
(blue) transfected with the wild-type LAR appeared as
rounded dying cells (Figure 4a,b). In contrast, less than
10% of the blue cells co-transfected with the truncated
LAR, or with the vector plasmid, appeared as rounded
cells. As was seen with the LAR-transfected cells, about
30% of the blue cells transfected with ICE appeared as
rounded cells (Figure 4b). The rounded cells obtained
following transfection with LAR or ICE were indistin-
guishable on the basis of morphology, suggesting that both
were undergoing apoptosis (Figure 4a and data not shown).
To verify that overexpression of LAR indeed induced cell
death, we expressed LAR under the control of the
tetracycline-suppressible promoter [33]. Our initial efforts
to use the fibroblast cell line 208F for the tetracycline
expression system failed because of the leaky activity of
the tetracycline-suppressible promoter in this cell line. We
then selected an osteosarcoma cell line U2OS, with which
the Tet-suppressible system has been successfully used
(L Zhu, personal communication).
Constructs expressing either wild-type or truncated LAR
were transfected into U2OS cells and stable cell clones,
which could be induced to express the two proteins, were
established. In general, comparable amounts of LAR
protein were induced in the two sets of transfectants.
Nevertheless, there were 5–20-fold variations in LAR
protein levels between clones compared with the level of
LAR in uninduced cells (Figure 5a). The LAR protein
was detectable after six hours of induction and reached its
maximum level 12–24 hours following induction, depend-
ing on the clone (data not shown).
When cultured in the presence of tetracycline, which
suppresses LAR expression, the parental U2OS cells and
the LAR tansfectants appeared as a flat monolayer of cells
(Figure 5b and data not shown). Rounded, floating cells
began to appear in the cultures transfected with wild-type
LAR, 12–24 hours after the induction of LAR expresion.
The floating cells stained positive with propidium iodide,
indicating that they were dead (Figure 5d,e). In the
majority of clones expressing wild-type LAR protein,
more than 50% of the cells in each culture died after LAR
overexpression for 48 hours (Figure 5c,f). In contrast,
there were no apparent morphological changes nor did
cell death occur in the cultures transfected with truncated
LAR under the same conditions (data not shown). The
percentage of cell death varied between clones but did
not correlate entirely with the level of LAR protein
(Figure 5a,c), indicating that cell death was not solely
caused by the high level of LAR protein that was
expressed in the cells. 
LAR-induced cell death is p53-independent but requires
caspase activity 
Cells that were induced to die by LAR overexpression
had the characteristic morphology of cells undergoing
apoptosis, including membrane blebbing, cell volume
loss, nuclear condensation and cell fragmentation
(Figure 6a and data not shown). To confirm the occur-
rence of DNA fragmentation, chromosomal DNA was iso-
lated from induced and uninduced cells and visualized by
agarose gel electrophoresis. The characteristic inter-
nucleosomal DNA fragmentation was apparent only in
LAR-induced cells (Figure 6d). DNA fragmentation was
further confirmed using the terminal-deoxynucleotidyl-
mediated dUTP nick end-labeling (TUNEL) assay.
About half of the rounded cells in the LAR-induced
culture were TUNEL-positive (Figure 6b). In contrast,
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Figure 4
Cell rounding induced by transient transfection of LAR. Rat fibroblast
208F cells were transiently co-transfected with a plasmid encoding the
β-galactosidase reporter and constructs containing no cDNA insert
(Vector), or cDNA inserts encoding the wild-type LAR, the truncated
LAR-∆TP, or ICE. The ratio of the reporter plasmid to the co-
transfected second plasmid was 1:5. Cells were fixed and stained with
X-gal 24 h after transfection. Transfected cells stain blue with X-gal.
(a) Examples of round cells (blue) resulting from LAR transfection.
Cells transfected with vector or wild-type LAR are as indicated. (b)
Proportion of cells that are round resulting from each transfection.
About 700 blue cells from each transfection were counted and the
number of rounded blue cells was expressed as a percentage of the
total number of blue cells.
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no TUNEL-positive cells were found in the uninduced
control culture (Figure 6c).
To understand the molecular basis of the LAR-induced cell
death, we investigated the involvement of several key mol-
ecules that have been implicated as playing key roles in
apoptotic processes. The requirement for functional p53 in
LAR-induced cell death was investigated by introducing
the LAR expression construct into another osteosarcoma
cell line, Saos2, in which the p53 gene was deleted.
Although the LAR protein level induced in the Saos2 cells
was not as high as in the U2OS cells (data not shown), LAR
induced similar apoptotic cell death in these p53-deficient
cells (Figure 7), indicating that p53 is not required for LAR-
induced apoptosis.
To investigate the involvement of caspases in LAR-induced
death, we induced LAR expression in the presence of
caspase inhibitors. LAR-induced cell death was inhibited by
ZVAD, a modified peptide which inhibits several caspases
[34], in a dose-dependent manner (Figure 8 and data not
shown). At a concentration of 50 µM, ZVAD completely
inhibited cell death as well as cell detachment (Figure 8a,b),
suggesting that cell detachment may be a consequence of
caspase activation. ZVAD had no apparent effect on unin-
duced cells (Figure 8a). We next determined which
member of the caspase family was required for the LAR-
induced cell death using specific caspase inhibitors. Cell
death was partially inhibited by the caspase-3 inhibitor
ZDEVD but not by the ICE inhibitor ZYVAD (Figure 8b).
Because ZVAD is more effective than ZDEVD, our data
suggest that LAR may induce apoptosis partly through acti-
vation of caspase-3, but other caspases may also be involved.
Caspase-3, but not ICE, is activated during LAR-induced
cell death
To confirm the above suggestion, we examined the
proteolytic activation of ICE and caspase-3 [35,36] upon
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Figure 5
Cell death induced by overexpression of LAR under the control of the
tetracycline-suppressible promoter. (a) Induction of LAR
overexpression. Clones of U2OS cells containing the tetracycline-
suppressible LAR cDNA expression constructs were induced to
express LAR by removing tetracycline from the medium. Cells, which
were stably transfected with the wild-type LAR construct (U2OS/LAR)
or the truncated LAR construct (U2OS/LAR-∆TP), were cultured in the
presence (Tet+) or absence (Tet–) of tetracycline for 24 h. Three
independent clones of cells were used for each LAR construct. Equal
amounts of total protein from these cells were analyzed by western
blotting using anti-LAR antiserum αN-130, which recognizes the
190 kDa precursor and the 145 kDa extracellular subunit of LAR.
Parental U2OS cells was used as a control. (b) Morphology of
U2OS/LAR cells in the absence of induction. (c–e) Massive cell death
occurred 24–48 h after induction of LAR overexpression. The dead
cells are shown under higher magnification in (d,e) and stained with
propidium iodide in (e). (f) Cell survival after LAR induction. Parental
U2OS cells and U2OS cells stably transfected with truncated LAR
(U2OS/LAR-∆TP) or wild-type LAR (U2OS/LAR) were seeded at
equal densities and cultured with or without tetracycline. Viable cells
after culture for 48 h were counted and the ratio of the number of
viable cells in Tet– cultures to the number in Tet+ cultures was
calculated and is presented in the graph as the percentage of cells
surviving. The data are mean values from three separate experiments.
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overexpression with LAR. We also investigated whether
poly(ADP-ribose) polymerase (PARP), a known substrate
of caspases was cleaved [36]. Cells were collected at differ-
ent time points after induction of LAR overexpression.
Cell lysates were analyzed by western blot analysis using
specific antibodies against ICE, caspase-3 and PARP.
Both caspase-3 and PARP were cleaved in the LAR-over-
expressing cells but not in the control cells (Figure 9).
The level of ICE protein, on the other hand, was not
affected by LAR overexpression (Figure 9), indicating
that caspase-3, but not ICE, was activated upon LAR
overexpression and might be the protease responsible for
LAR-induced apoptosis.
Overexpression of LAR does not affect cell adhesion
Activation of caspases has been shown to occur during
anoikis, a form of apoptosis caused by detachment of cells
from their substratum [37]. The structure of the LAR
extracellular domain suggests that LAR might interact
with extracellular matrix proteins and it is therefore possi-
ble that overexpression of LAR might interfere with cell
adhesion. LAR-induced cell death could have been
caused by disrupted cell adhesion and the cells could
have died through anoikis. Nevertheless, the observation
that both cell death and cell detachment were inhibited
by caspase inhibitors (Figure 8) suggested that LAR-
induced cell death might not be a consequence of dis-
rupted cell adhesion. We therefore investigated effects of
LAR overexpression on cell adhesion. Uninduced cells
and cells induced to express LAR for 8–24 hours were
plated onto microtiter plates coated with various concen-
trations of fibronectin. Adherent cells were examined
after incubation for 30 minutes. No obvious changes in
cell adhesion to fibronectin were observed following
induction of LAR overexpression (Figure 10 and data not
shown). Similar results were obtained when laminin or
collagen were used as substrates (data not shown). We
also tested whether the parental U2OS cells could
undergo anoikis by plating the cells onto poly(2-hydrox-
yethyl methacrylate), which prevents cell attachment
[38]. The cells were stained with propidium iodide after
incubation for 24 hours. No significant cell death was
detected during this period (data not shown). In contrast,
LAR-induced cell death occurred less than 12 hours after
252 Current Biology, Vol 8 No 5
Figure 6
Characterization of LAR-induced cell death.
(a) Morphology of LAR-overexpressing cells is
typical of apoptotic cells with membrane
blebbing and fragmented cell bodies.
(b) Result of TUNEL assay on induced, LAR-
overexpressing cells. Apoptotic cells appear
yellow because of double staining by
fluorescein (green) and propidium iodide (red).
(c) Result of TUNEL assay on control
uninduced cells, which show only propidium
iodide staining. (d) Agarose gel
electrophoresis of DNA from control uninduced
cells (lane 2) or from the induced, LAR-
overexpressing dead cells (lane 3). Evidence
for DNA fragmentation characteristic of
apoptosis is the laddering of the DNA sample
from LAR-overexpressing cells (lane 3). The
1 kb DNA molecular weight ladder is in lane 1.
Figure 7
LAR-induced cell death in cells that are defective for the p53 gene.
Parental Saos2 osteosacoma cells and cells stably transfected with
the wild-type LAR cDNA under the control of the tetracycline-regulated
promoter (Saos2/LAR) were each seeded equally into pairs of cultures
with or without tetracycline. After 48 h, viable cells from all cultures
were counted and the ratio of viable cells from the Tet– and the Tet+
cultures was calculated for each cell line and is presented as the
percentage of cells surviving. The data are presented as mean values
from three independently isolated transfectants.
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induction of LAR overexpression, suggesting that LAR
may not induce cell death through anoikis.
Discussion
We have demonstrated here that overexpression of LAR
activates caspase-3 and induces apoptosis, raising the
intriguing possibility that LAR might play a role in regu-
lating growth/survival signals and controlling cell
death/survival in vivo. The ability of LAR to induce apop-
tosis requires its phosphatase domain — a truncated
version of LAR lacking the catalytic domain does not
induce apoptosis and the overexpression of this mutant is
well-tolerated by the cells, suggesting that overproduction
of the LAR protein per se is not sufficient to cause cell
death. We believe that dephosphorylation of certain
tyrosine phosphorylated proteins by increased LAR
phosphatase activity is the key to caspase activation and
induction of cell death. Although the direct substrates of
LAR have yet to be identified, we present evidence to
suggest that LAR may activate the caspases directly to
induce apoptosis. How might overexpression or activation
of LAR induce apoptosis? There are at least three possible
ways. The first possible mechanism comes from the
finding that tyrosine phosphorylation is critical for signal
transduction of many important growth factors, such as the
platelet-derived growth factor (PDGF), the epidermal
growth factor (EGF), the fibroblast growth factor (FGF)
and IGF. It has been reported that LAR might directly
dephosphorylate the insulin receptor [11] and that LAR
modulates signal transduction from a number of growth
factor receptor tyrosine kinases [9]. We observed that
LAR-induced cell death can be partially inhibited by basic
FGF (our unpublished observations), suggesting at least
that activation of some receptor tyrosine kinases can over-
come the cell death caused by overexpression or activation
of the LAR tyrosine phosphatase. Therefore, LAR might
dephosphorylate one or several of the growth factor recep-
tors or their downstream signaling components and thus
block growth and/or survival signals, which might lead to
activation of caspase and induction of cell death [39]. 
Second, cell adhesion and signal transduction mediated by
cell-adhesion molecules are also critical for cell survival
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Figure 8
Inhibition of LAR-induced cell death by caspase inhibitors. The
U2OS/LAR stable transfectant cells were cultured in the presence
(Tet+) or the absence (Tet–) of tetracycline and with or without the
general caspase inhibitor ZVAD (50 µM), caspase-3 inhibitor ZDEVD
(250 µM), or ICE inhibitor ZYVAD (250 µM) respectively for 12 h. (a)
Morphology of LAR+ (Tet–) and LAR– (Tet+) cells in the presence or
absence of ZVAD. (b) Proportion of cells that are viable after induction
of LAR overexpression and treatment with the caspase inhibitors.
Viability was calculated as the ratio (%) of the number of viable cells in
Tet– cultures to the number in Tet+ cultures. The data are mean values
from three separate experiments.
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Figure 9
Activation of caspase-3 by LAR induction. The U2OS/LAR stable
transfectants were cultured in the presence or absence of tetracycline
for the indicated times. Both adherent and floating cells were
harvested and equal amounts of total cellular protein were resolved by
SDS–PAGE followed by western blot analysis. The blot was
sequentially probed with different antibodies as indicated. Notice the
time-dependent reduction of caspase-3 and the appearance of the
PARP cleavage product (arrowhead) in the Tet– (LAR+) culture. D,
protein isolated from floating dead cells. Anti-tubulin antibody was
used as a control to show equal loading of protein between lanes.
Time 6 h 9 h 12 h D
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[40–43]. Mutation of DLAR results in defects in axonal
guidance, suggesting that DLAR is involved in cell–cell or
cell–matrix signaling and/or adhesion [16]. Serra-Pages et
al. [13] reported that the LAR protein is localized at focal
adhesions. It is thus possible that the LAR phosphatase
has a role in regulating cell adhesion and/or signal
transduction mediated by cell-adhesion molecules.
Because disruption of cell adhesion during anoikis causes
activation of caspases [37,44,45], cell death could occur as
a result. Our data, however, show that LAR overexpres-
sion has no effect on cell adhesion and that LAR-induced
cell death and cell detachment are inhibited by caspase
inhibitors. It is therefore unlikely that LAR induces cell
death by interfering with cell adhesion. Nevertheless, our
data does not exclude the possibility that LAR affects
signal transduction mediated by cell-adhesion molecules.
This might limit growth signals or create conflicting
signals through the focal adhesion complexes, with apop-
tosis as the consequence. 
Last but not least, LAR might activate caspases and cause
cell to die through a novel mechanism. Yang et al. [46]
have reported that loss of substrate attachment and apop-
tosis of endothelial cells following removal of growth
factors are associated with dephosphorylation of tyrosine
residues at the cell periphery. The dephosphorylation of
total cellular proteins that accompanies apoptosis can be
blocked by orthovanadate, an inhibitor of PTPs [46,47].
Orthovanadate has also been found to block DNA frag-
mentation, a hallmark of apoptosis [48], and is as effective
as basic FGF in preventing the apoptosis of endothelial
cells that results from treatment with TNFα [49]. Thus,
phosphorylation of certain proteins on tyrosine residues is
likely to be important for cell survival. We hypothesize
that LAR overexpression leads to dephosphorylation of
protein(s) that are critical for cell survival resulting in cell
death and cell detachment.
Our data also suggest that LAR-induced apoptosis does
not require functional p53. In apoptosis that is induced by
DNA damage, p53 plays a critical role [50] but in other
cases of apoptosis induced, for example, by glucocorti-
coids or phorbol ester, p53 is not required, indicating that
both p53-dependent and p53-independent apoptotic path-
ways exist [51,52]. Our results provide another example of
apoptosis that is p53-independent and not induced by
DNA damage. We have also analyzed possible effects of
LAR on cell-cycle progression prior to cell death and
found no evidence indicating that LAR overexpression
causes cells to arrest at a particular phase of the cell cycle
(our unpublished observations). Thus, LAR-induced cell
death might not be a consequence of deregulated cell-
cycle progression.
Conclusions
The present study provides the first evidence of the
involvement of a receptor-like PTP in regulating cell
death. Our results show that, when overexpressed, LAR
can activate the caspase pathway directly, without affect-
ing cell adhesion, and can induce p53-independent apop-
tosis. We believe that overexpression of LAR increases
the total activity of LAR, resulting in dephosphorylation
of a set of proteins which are crucial for cell survival. This
study provides a foundation for identifying these impor-
tant molecules and to link protein tyrosine phosphoryla-
tion with the caspase protease pathway.
Materials and methods
Plasmid construction and transfection 
Two mammalian cell expression vectors, pBabe [53], which expresses
inserted genes from the constitutive moloney murine leukemia virus
long terminal repeat (LTR) promoter, and pUHD10-3 [33], which con-
tains a tetracycline-suppressible promoter, were used to generate the
two sets of LAR expression constructs. The wild-type LAR cDNA
expression constructs were generated by ligating a 6.3 kb SalI–BamHI
fragment, which contains the 240 bp 5′ untranslated region (UTR), the
entire 5661 bp protein-coding region, and the 450 bp 3′ UTR of the rat
LAR cDNA [2], into the two expression vectors. LAR-∆TP constructs
were generated by ligating a 3.8 kb SalI–SacI LAR cDNA fragment,
which contains the same 5′ UTR followed by 3524 bp of protein
coding sequences, into the same expression vectors. Cell transfections
were done using the standard calcium phosphate precipitation method
[54]. For transient transfections of COS-7 cells, 5 µg of LAR expres-
sion plasmid DNAs were used in each transfection assay. Cell lysates
were harvested 24 h after transfection. For transient transfection
assays of the 208F cells, exponentially growing cells were co-trans-
fected with 1 µg β-galactosidase expression plasmid and 5 µg LAR or
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Figure 10
Effects of LAR overexpression on cell adhesion. Microtiter plates were
coated with fibronectin at the indicated concentrations. Cells were
precultured in normal tissue culture plates for 8 h with or without
tetracycline to induce LAR expression. Both induced (LAR+) and
uninduced (LAR–) cells were then trypsinized, and each sample was
plated in triplicate into three wells of the microtiter plate per
concentration of fibronectin, and then incubated for 30 min at 37oC as
described in the Materials and methods. Nonadherent cells were
removed. The remaining adherent cells were fixed, stained with crystal
violet and quantified by measuring the optical density at 562 nm.
Representative mean data are shown for three wells from one of three
separate experiments.
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ICE cDNA expression plasmids. The cells were fixed for β-galactosi-
dase staining 24 h after transfection. To generate stable 208F, U2OS,
and Saos2 transfectants, the cells were transfected with 2.5 µg
plasmid DNA per 5 × 104 cells on a 35 mm plate. The cells were
diluted into 100 mm plates 12 h after transfection and were selected in
the presence of puromycin (Sigma) at 1 µg/ml for 1 week. The individ-
ual clones were then isolated and propagated. The U2OS and Saos2
transfectant cell clones were maintained in 10% FBS/DMEM with
250 µg/ml Geneticin (GIBCO), 0.2 µg/ml puromycin (Sigma), and
1 µg/ml tetracycline.
Cells cultures 
The rat embryonic fibroblast cell line 208F [55] and the COS-7 cells
were grown in 10% CF (GIBCO)/DMEM (GIBCO). The two human
osteosarcoma cell lines U2OS and Saos2, which were stably trans-
fected with the tetracycline-controlled transactivator expression
plasmid pUHD15-1 [33], were gifts from Liang Zhu and were main-
tained in 10% FBS/DMEM (GIBCO) with 250 µg/ml Geneticin
(GIBCO). 
β-Galactosidase staining
Cells were fixed with 0.5% glutaraldehyde/PBS for 10 min at room
temperature, washed 3 times with PBS, and then incubated in X-gal
staining solution (5 mM potassium ferricyanide, 5 mM potassium ferro-
cyanide, 1 mM MgCl2, 1 mg/ml X-gal in PBS) for 2–4 h at 37°C. 
Induction and analysis of apoptosis 
To induce LAR expression, cells were trypsinized and washed twice
with medium, and plated into tetracycline-free medium at 5 × 104 cells
per 35 mm diameter dish. Cell viability were measured by plating equal
numbers of cells into Tet+ and Tet– media and then cultured. At the
end of the induction, viable cells, which remain attached to the dish,
were trypsinized and counted with a Coulter counter. The ratio of the
number of viable cells in Tet– cultures to the number in Tet+ cultures
were calculated and presented as the percentage of cells surviving.
Propidium iodide staining was performed by adding 1% volume of
69 µM propidium iodide in 38 mM sodium citrate pH 7.3  to the dishes
followed by incubation for 10 min at 37°C. TUNEL analysis of DNA
fragmentation was performed using an in situ apoptosis detection kit
(ApopTag) following the instructions recommended by the manufac-
turer (Oncor). Gel electrophoretic analysis of DNA fragmentation was
performed on a 1.2% agarose gel using genomic DNA extracted from
detached cells with the Easy DNA kit (Invitrogen). The caspase
inhibitors were purchased from Enzyme Systems. To test the effects of
the caspase inhibitors on LAR-induced cell death, the U2OS/LAR
transfectants were cultured in pairs of Tet+ and Tet– cultures and in
the presence of the caspase inhibitors, 50 µM Z-Val-Ala-Asp-CH2F,
250 µM Z-Asp-Glu-Val-Asp-CH2F or 250 µM Z-Tyr-Val-Ala-Asp-CH2F
for 12 h.
Protein extraction, immunoprecipitation, and immunoblotting
Metabolic labeling of cells with [35S]methionine and immunoprecipi-
tation was performed as described [2]. Briefly, [35S]methionine-
labeled cells were washed with PBS and lysed in cold RIPA buffer
(150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS,
50 mM Tris pH 8.0), and immunoprecipitated with anti-LAR antibody.
The proteins were resolved by 6% gels by SDS–PAGE. For
immunoblotting, Laemmli sample buffer was added directly to the
cells to a final concentration of 106 cells/ml. The cell lysates were
boiled for 5 min and aliquots equal to approximately 5 × 104 cells
were subjected to SDS–PAGE (6% or 12% gels) and transferred to
nitrocellulose membrane. The membranes were blocked with 5% non-
fat dry milk in 10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween 20 for
1 h at room temperature, incubated with appropriate primary antibod-
ies for 2 h at room temperature or overnight at 4°C, followed by either
secondary antibodies conjugated to alkaline phosphatase or horse-
radish peroxidase (Promega) for 1 h at room temperature. Proteins
were detected with the ProtoBlot Western Blot AP System
(Promega) or the ECL kit (Amersham). 
Antibodies
Rabbit polyclonal antisera αC-292 and αN-130 are anti-LAR antisera
raised against synthetic peptides of the C-terminus and the N-terminus
of the LAR protein respectively [2]. and were used at 1:500 dilution.
Rabbit polyclonal antisera α−294 was raised against a E. coli-pro-
duced full length LAR protein in a similar way as described in [2] and
were used at 1:500 dilution. Mouse monoclonal anti-ICE, anti-PARP,
and anti-caspase-3 were used at 1:2000 dilution. Mouse monoclonal
antibody α-tubulin was purchased from Sigma and used at 1:10000
dilution.
Adhesion assays
Adhesion assays were carried out according to Cary et al. [56]. Briefly,
96-well Immunol-4 microtiter plates (Dynatech Laboratories) were pre-
coated with human plasma fibronectin (Gibco BRL) at various concen-
trations in DMEM for 60 min at room temperature, washed twice with
DMEM, and blocked with 1% BSA for 60 min at 37°C. Cells were ini-
tially cultured in regular tissue culture plates with or without tetracycline
for 8 h to induce LAR expression. After induction, both LAR+ and
LAR– cells were trypsinized, washed once with DMEM containing
0.5 mg/ml soybean trypsin inhibitor (Sigma), twice with DMEM contain-
ing 1% BSA, resuspended in DMEM, and then added to the fibronectin
coated plates at 5 × 104 cells per well. An aliquot of cells at this point
was saved for confirming LAR expression. After 30 min incubation at
37°C in a humidified atmosphere containing 5% CO2, nonadherent
cells were washed twice with PBS, and adherent cells were fixed with
70% ethanol for 20 min. Cells were stained with 5 mg/ml crystal violet
in 20% methanol for 10 min and washed 4 times with PBS. Bound
stain was extracted with 0.1 M sodium citrate pH 4.2 for 30 min. The
optical density (OD) was read at 562 nm. The background OD value
from a well without cells was subtracted from the OD value for each
well. LAR expression was confirmed by western blot analysis.
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